• Publications
  • Influence
Revised international prognostic scoring system for myelodysplastic syndromes.
TLDR
This revised IPSS-R comprehensively integrated the numerous known clinical features into a method analyzing MDS patient prognosis more precisely than the initial IPSS and should prove beneficial for predicting the clinical outcomes of untreated MDS patients and aiding design and analysis of clinical trials in this disease.
Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients
TLDR
In older patients with AML, decitabine improved response rates compared with standard therapies without major differences in safety, and an unplanned survival analysis showed a benefit for decit abine, which was not observed at the time of the primary analysis.
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.
TLDR
Within the myelodysplastic syndrome (MDS) work package of the European LeukemiaNet, an Expert Panel was selected according to the framework elements of the National Institutes of Health Consensus Development Program and Guidelines were developed on the basis of a list of patient- and therapy-oriented questions.
C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor.
TLDR
C-reactive protein (CRP), an acute-phase reactant that markedly increases its serum concentration in response to inflammatory stimuli, induced monocytes to express tissue factor (TF), a potent procoagulant.
Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis
TLDR
The clinical course of refractory anemia with ring sideroblasts and marked thrombocytosis is better than that of refracted anemia without ring siders, and worse than those of essential thromBocythemia.
Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow
TLDR
CyA could offer an alternative treatment for certain MDS patients with RA regardless of hyper‐, normo‐ or hypo‐cellularity of bone marrow (BM), who were treated with cyclosporin A (CyA).
BCL11A deletions result in fetal hemoglobin persistence and neurodevelopmental alterations.
TLDR
The study of 3 patients with rare microdeletions of 2p15-p16.1 who presented with an autism spectrum disorder and developmental delay and orthogonal genetic data demonstrates that BCL 11A plays a central role in silencing HbF in humans and implicates BCL11A as an important factor for neurodevelopment.
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.
TLDR
CC-486 maintenance therapy was associated with significantly longer overall and relapse-free survival than placebo among older patients with AML who were in remission after chemotherapy.
The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute
TLDR
QUAZAR AML-001 (NCT01757535), a phase III international, randomized, double-blind, placebo (PBO)-controlled study evaluating CC-486 as maintenance therapy in pts aged ≥55 years with AML in first remission following IC, demonstrated significant improvements in OS and RFS.
...
...